High rates of resumption of injecting drug use following release from prison among men who injected drugs before imprisonment.

"DECLARATION OF INTERESTS M.S. has received investigator‐initiated funding from Gilead Sciences, AbbVie and Bristol Myers Squibb and consultant fees from Gilead Sciences for activities unrelated to this work. P.D. has received investigator‐driven funding from Gilead Sciences for work related to hepatitis C treatment and an untied educational grant from Indivior for work related to the introduction of buprenorphine/naloxone into Australia. He has also served as an unpaid member of an Advisory Board for an intranasal naloxone product. The remaining authors declare that they have no conflicts of interest. Open access publishing facilitated by Monash University, as part of the Wiley ‐ Monash University agreement via the Council of Australian University Librarians."

"Funding information The Prison and Transition Health Cohort Study was funded by a National Health and Medical Research Council (NHMRC) Project Grant (APP1029915). M.C. is the recipient of an NHMRC post‐graduate award and a Monash Addiction Research Centre PhD top‐up scholarship. M.S. and P.D. are recipients of NHMRC Senior Research Fellowships. We gratefully acknowledge the support provided to the Burnet Institute by the Victorian Government Operational Infrastructure Support Program. Funding information National Health and Medical Research Council, Grant/Award Number: APP1029915"